European Medicines Agency (EMA) announcement
The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union for mCombriax, a messenger RNA vaccine for protecting people aged 50 years and older against COVID-19 and seasonal influenza.
mCombriax works like other vaccines by preparing the body to defend itself against infection. It contains messenger RNA with instructions for making proteins found on SARS-CoV-2 and the following seasonal influenza viruses: influenza type A-H1N1, influenza type A-H3N2 and influenza type B of the Victoria lineage.
As the first combined COVID-19/influenza vaccine, mCombriax provides people with the option of having a single shot to protect against both illnesses.
Read the full announcement here.
Source : European Medicines Agency
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.